Enanta reports positive Phase 2b topline data for zelicapavir in high-risk RSV adults

ENANTA PHARMACEUTICALS INC

Phase 2b study of zelicapavir (formerly EDP-938) met primary endpoint in high-risk adults with RSV.
Topline results announced September 29, 2025; detailed data presented in slide presentation.
Zelicapavir is an oral antiviral; no specific efficacy or safety numbers disclosed in the 8-K.
Positive outcome supports advancement; further details expected in future medical meetings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.